STAT+: Pharmalittle: We’re reading about U.S. pressuring Germany on drug prices, FDA upheaval and biotech clinical trials, and more

The article discusses recent developments in the biotech sector, including U.S. pressure on Germany regarding drug pricing and ongoing changes within the FDA that may impact clinical trials. These issues are critical as they reflect the evolving landscape of drug regulation and pricing strategies in the biotech industry. The piece also hints at broader implications for healthcare and pharmaceutical practices.